These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21129498)

  • 41. Outsourcing chemical synthesis in the drug discovery process.
    Festel G
    Drug Discov Today; 2011 Mar; 16(5-6):237-43. PubMed ID: 21262378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
    Lienhardt C; Vernon A; Raviglione MC
    Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knowledge-based chemoinformatic approaches to drug discovery.
    Ghose AK; Herbertz T; Salvino JM; Mallamo JP
    Drug Discov Today; 2006 Dec; 11(23-24):1107-14. PubMed ID: 17129830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reaping the benefits of biomedical research: partnerships required.
    Portilla LM; Alving B
    Sci Transl Med; 2010 Jun; 2(35):35cm17. PubMed ID: 20538616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel in silico approach to drug discovery via computational intelligence.
    Hecht D; Fogel GB
    J Chem Inf Model; 2009 Apr; 49(4):1105-21. PubMed ID: 19348414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetics in drug discovery and development: a translational perspective.
    Roses AD
    Nat Rev Drug Discov; 2008 Oct; 7(10):807-17. PubMed ID: 18806753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.
    Mondal MS; Gabriels J; McGinnis C; Magnifico M; Marsilje TH; Urban L; Collis A; Bojanic D; Biller SA; Frieauff W; Martus HJ; Suter W; Bentley P
    Toxicol Sci; 2010 Nov; 118(1):71-85. PubMed ID: 20631060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The anti-intellectual effects of intellectual property.
    Lipinski CA
    Curr Opin Chem Biol; 2006 Aug; 10(4):380-3. PubMed ID: 16829159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cooperation between practice and academia: the self-concept of nursing and scientific experts].
    Panfil EM
    Pflege Z; 2007 Jun; 60(6):324-7. PubMed ID: 17608044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration.
    Vitiello B; Heiligenstein JH; Riddle MA; Greenhill LL; Fegert JM
    Biol Psychiatry; 2004 Jul; 56(1):3-9. PubMed ID: 15219466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Drug development--from receptor research to therapy].
    Lammintausta R; Scheinin M
    Duodecim; 1998; 114(10):957-66. PubMed ID: 11524784
    [No Abstract]   [Full Text] [Related]  

  • 56. Incentives for Starting Small Companies Focused on Rare and Neglected Diseases.
    Ekins S; Wood J
    Pharm Res; 2016 Apr; 33(4):809-15. PubMed ID: 26666772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transfer from research/academia to clinical/regulated.
    Chowdhury F; Williams A
    Bioanalysis; 2016 Oct; 8(20):2169-76. PubMed ID: 27628669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time will tell—are innovative approaches hastening and improving drug development?
    Eur Heart J; 2012 Jan; 33(1):2-4. PubMed ID: 22210688
    [No Abstract]   [Full Text] [Related]  

  • 59. Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies.
    Gardell SJ; Roth GP; Kelly DP
    J Cardiovasc Transl Res; 2010 Oct; 3(5):431-7. PubMed ID: 20625868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Engaging basic scientists in translational research.
    Hobin JA; Galbraith RA
    FASEB J; 2012 Jun; 26(6):2227-30. PubMed ID: 22653563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.